Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 15;98(2):279–284. doi: 10.1172/JCI118790

Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

P thor Straten 1, J C Becker 1, T Seremet 1, E B Bröcker 1, J Zeuthen 1
PMCID: PMC507428  PMID: 8755635

Abstract

The T cell receptor (TCR) BV variable (V) gene repertoire of tumor infiltrating lymphocytes (TIL) found in progressive and regressive regions of the same primary human melanomas were characterized by reverse transcription coupled polymerase chain reaction (RT-PCR). After surgery, the tumors were divided into different parts which were judged as regressive or progressive regions by visual inspection. Subsequently this diagnosis was confirmed by histology. From a total of four primary melanomas analyzed, 2 were drawn to be HLA-A2+. Only relatively few BV-gene families were expressed at significant levels in each of the samples. Comparison of the BV-expression in regressive versus progressive regions of the same tumor revealed major differences in all cases examined. Direct sequencing of RT-PCR products indicated that highly expressed BV-gene families were of clonal origin in both the regressive and progressive regions. Together, these data strongly suggest the occurrence of clonal T cell responses in both regressive and progressive areas of the same primary tumor. The differences in expression of certain BV-genes may correlate with the functional activity of certain populations of tumor-infiltrating T cells.

Full Text

The Full Text of this article is available as a PDF (264.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker J. C., Czerny C., Bröcker E. B. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol. 1994 Oct;6(10):1605–1612. doi: 10.1093/intimm/6.10.1605. [DOI] [PubMed] [Google Scholar]
  2. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  3. Clark W. H. Tumour progression and the nature of cancer. Br J Cancer. 1991 Oct;64(4):631–644. doi: 10.1038/bjc.1991.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cole D. J., Weil D. P., Shamamian P., Rivoltini L., Kawakami Y., Topalian S., Jennings C., Eliyahu S., Rosenberg S. A., Nishimura M. I. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 1994 Oct 15;54(20):5265–5268. [PubMed] [Google Scholar]
  5. Cole W. H. Relationship of causative factors in spontaneous regression of cancer to immunologic factors possibly effective in cancer. J Surg Oncol. 1976;8(5):391–411. doi: 10.1002/jso.2930080506. [DOI] [PubMed] [Google Scholar]
  6. Cole W. H. Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr. 1976 Nov;44:5–9. [PubMed] [Google Scholar]
  7. Ferradini L., Roman-Roman S., Azocar J., Avril M. F., Viel S., Triebel F., Hercend T. Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res. 1992 Sep 1;52(17):4649–4654. [PubMed] [Google Scholar]
  8. Ferrone S., Marincola F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995 Oct;16(10):487–494. doi: 10.1016/0167-5699(95)80033-6. [DOI] [PubMed] [Google Scholar]
  9. Johnston R. F., Pickett S. C., Barker D. L. Autoradiography using storage phosphor technology. Electrophoresis. 1990 May;11(5):355–360. doi: 10.1002/elps.1150110503. [DOI] [PubMed] [Google Scholar]
  10. Kelly J. W., Sagebiel R. W., Blois M. S. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer. 1985 Nov 1;56(9):2287–2291. doi: 10.1002/1097-0142(19851101)56:9<2287::aid-cncr2820560924>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  11. Kirkin A. F., Petersen T. R., Olsen A. C., Li L., thor Straten P., Zeuthen J. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother. 1995 Aug;41(2):71–81. doi: 10.1007/BF01527402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kurt R. A., Park J. A., Panelli M. C., Schluter S. F., Marchalonis J. J., Carolus B., Akporiaye E. T. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. J Immunol. 1995 Apr 15;154(8):3969–3974. [PubMed] [Google Scholar]
  13. Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H., Boon T., Coulie P. G. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995 Feb;25(2):340–347. doi: 10.1002/eji.1830250206. [DOI] [PubMed] [Google Scholar]
  14. Lüscher U., Filgueira L., Juretic A., Zuber M., Lüscher N. J., Heberer M., Spagnoli G. C. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer. 1994 May 15;57(4):612–619. doi: 10.1002/ijc.2910570428. [DOI] [PubMed] [Google Scholar]
  15. Mackensen A., Ferradini L., Carcelain G., Triebel F., Faure F., Viel S., Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993 Aug 1;53(15):3569–3573. [PubMed] [Google Scholar]
  16. Nanda N. K., Arzoo K. K., Geysen H. M., Sette A., Sercarz E. E. Recognition of multiple peptide cores by a single T cell receptor. J Exp Med. 1995 Aug 1;182(2):531–539. doi: 10.1084/jem.182.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nanda N. K., Arzoo K. K., Sercarz E. E. In a small multideterminant peptide, each determinant is recognized by a different V beta gene segment. J Exp Med. 1992 Jul 1;176(1):297–302. doi: 10.1084/jem.176.1.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Romero P., Pannetier C., Herman J., Jongeneel C. V., Cerottini J. C., Coulie P. G. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med. 1995 Oct 1;182(4):1019–1028. doi: 10.1084/jem.182.4.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Russo V., Traversari C., Verrecchia A., Mottolese M., Natali P. G., Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer. 1995 Jun 22;64(3):216–221. doi: 10.1002/ijc.2910640313. [DOI] [PubMed] [Google Scholar]
  20. Salvi S., Segalla F., Rao S., Arienti F., Sartori M., Bratina G., Caronni E., Anichini A., Clemente C., Parmiani G. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 1995 Aug 1;55(15):3374–3379. [PubMed] [Google Scholar]
  21. Schøller J., thor Straten P., Birck A., Siim E., Dahlström K., Drzewiecki K. T., Zeuthen J. Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother. 1994 Oct;39(4):239–248. doi: 10.1007/BF01525987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sensi M., Parmiani G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today. 1995 Dec;16(12):588–595. doi: 10.1016/0167-5699(95)80082-4. [DOI] [PubMed] [Google Scholar]
  23. Sensi M., Traversari C., Radrizzani M., Salvi S., Maccalli C., Mortarini R., Rivoltini L., Farina C., Nicolini G., Wölfel T. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5674–5678. doi: 10.1073/pnas.92.12.5674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thor Straten P., Schøller J., Hou-Jensen K., Zeuthen J. Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer. 1994 Jan 2;56(1):78–86. doi: 10.1002/ijc.2910560115. [DOI] [PubMed] [Google Scholar]
  25. Weidmann E., Elder E. M., Trucco M., Lotze M. T., Whiteside T. L. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer. 1993 May 28;54(3):383–390. doi: 10.1002/ijc.2910540306. [DOI] [PubMed] [Google Scholar]
  26. Zemmour J., Parham P. HLA Class I nucleotide sequences, 1992. Immunobiology. 1993 Jan;187(1-2):70–101. doi: 10.1016/S0171-2985(11)80246-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES